Scil Proteins is a biopharmaceutical company whose key value driver is its proprietary
Affilin® drug discovery platform. Scil Proteins has longstanding expertise in protein manufacturing, and their certified
GMP production facility generates revenue through long-term customer contracts.
02.02.2012:
Rainer Rudolph Foundation Launches
Search for Young Talents in Protein Biotechnology. Read more...
17.01.2012:
Scil Proteins has
signed a supply agreement with Actavis, one of the world's leading generic
pharmaceutical companies, for the future manufacturing of Reteplase. Read more...
